Ambrisentan is an orally active, propanoic acid-class, ERA selective for the endothelin A (ETA) receptor. Endothelin plays a significant role in the pathophysiology of PAH.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Ambrisentan is the active ingredient of these drugs:
Australia Austria Brazil Canada Cyprus
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):